Across TCGA pan-cancer cohorts, TMEM242 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TMEM242 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher TMEM242 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM242 expression acts as an unfavorable survival marker.
SARC are the cancer types where TMEM242 Mutation most reproducibly stratifies survival.